Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

Study of Mk-7684A + Etoposide/Platinum vs Atezolizumab + Etoposide/Platinium in SCLC

A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer

Disease Types: Lung

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer

For More Information:

https://clinicaltrials.gov/ct2/show/NCT05224141?term=A+Phase+3%2C+Randomized%2C+Double-Blind+Study+of+MK-7684A+in+Combination+with+Etoposide+and+Platinum+Followed+by+MK-7684A+vs+Atezolizumab+in+Combination+with+Etoposide+and+Platinum+Followed+by+Atezolizumab&cond=Small+Cell+Lung&draw=2&rank=1